New bivalent vaccine approved for autumn booster campaign

The Pfizer-BioNTech bivalent vaccine has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Joint Committee on Vaccination (JCVI) has advised its use for the autumn booster campaign.

Research indicates that the Pfizer-BioNTech bivalent vaccine produces a marginally higher immune response against some variants than the Pfizer-BioNTech mRNA Original ‘wild-type’ vaccine.

Professor Wei Shen Lim, Chair of COVID-19 immunisation on the JCVI, said: "It is very encouraging that more vaccines continue to become available and we now have another option to add to the vaccines already advised for the autumn booster campaign.

"Winter is typically the time of greatest threat from respiratory infections. We strongly encourage everyone who is eligible to have their booster vaccine this autumn when it is offered. This is our best defence against becoming severely ill from COVID-19."

Image: Pixabay

Event Diary

This story was first published in digitalhealth.net

Supplier Profiles

CDC success at Victoria Infirmary, Northwich creates ideal model for future patient pathway reforms

Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients

Gain valuable insight with Adveco for gas to electric decarbonisation projects

Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho